On Demand Therapeutics

Breaking Through Challenges in Ophthalmic Drug Delivery

Current drug therapies for severe retinal diseases are delivered through repeated intravitreal injections, which is a suboptimal, inefficient, and unsustainable treatment option due to the pain, time, and financial burden placed on both patients and physicians. To address this, On Demand Therapeutics (ODTx™) is developing a small, injectable ophthalmic implant containing multiple, laser-activated reservoirs designed for the on-demand, physician-controlled release of ocular drug therapies to the back of the eye.

Learn More

A Non-Invasive and Precise Way of Treating Retinal Disease

The ODTx™ device fulfills the unmet need for sustainable and interactive therapies that precisely and effectively treat severe retinal diseases. After the device is injected, the ophthalmologist decides at subsequent office visits when to non-invasively release additional drug by focusing a laser beam on the selected reservoir to open it, allowing the drug to elute from the reservoir into the eye.

Learn More

Multiple Reservoirs Deliver Multiple Benefits

Protein therapeutics provide the most effective and promising treatment for retinal diseases, but these drugs have limited stability in the body and are therefore difficult to deliver over extended durations. The multiple reservoirs of the ODTx™ implant are designed to provide drug therapy for an extended duration of a year, or more, by sealing the drug away from the harsh environment of the body until needed. No other delivery system has this capability.

Learn More

Partnerships Creating Retinal Disease Solutions

If you’d like to help transform retinal drug therapy by becoming a partner with ODTx™, please contact us today.

Contact Us

Revolutionizing Retinal Drug Therapy

Retinal OptionsThe treatment of retinal disease faces a serious challenge as current ocular drug therapy strategies are based on frequent intravitreal injections, which are undesirable and unsustainable due to the pain, time, and financial burden placed on patients and physicians. Implantable polymeric depots and devices are limited to delivering steroids and other small molecules, and such polymer products have no mechanism for real-time control of dosing, leading to significant side effects such as glaucoma or cataracts. Protein or complex macromolecule therapeutics provide the most effective and promising treatment for retinal diseases, but these drugs have limited stability in the body and are therefore difficult to deliver over extended durations. Addressing these ophthalmic drug delivery challenges is exactly why On Demand Therapeutics, Inc. (ODTx™) was created.

The ODTx device is a biocompatible, injectable implant made up of multiple, sealed reservoirs to store and protect protein and macromolecular drugs until a laser is used to initiate the on-demand release of the drug to the back of the eye. This breakthrough technology is implanted into the periphery of the vitreous and enables multiple, physician-controlled administrations of drug for an extended duration of a year, or more, through a simple, non-invasive, office-based laser procedure.

Register for Updates

Name:

E-mail:

Submit

Share ODTx

Select an icon to share this page with colleagues.